Whales with a lot of money to spend have taken a noticeably bearish stance on Gilead Sciences.
Looking at options history for Gilead Sciences GILD we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $63,675 and 6, calls, for a total amount of $189,207.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $80.0 for Gilead Sciences during the past quarter.
Analyzing Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale trades within a strike price range from $70.0 to $80.0 in the last 30 days.
Gilead Sciences Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| GILD | PUT | TRADE | BEARISH | 02/09/24 | $80.00 | $38.0K | 15 | 261 |
| GILD | CALL | SWEEP | BEARISH | 03/15/24 | $77.50 | $37.6K | 506 | 157 |
| GILD | CALL | TRADE | BEARISH | 08/16/24 | $75.00 | $35.0K | 9 | 40 |
| GILD | CALL | TRADE | BEARISH | 01/16/26 | $70.00 | $31.7K | 288 | 20 |
| GILD | CALL | TRADE | BULLISH | 06/21/24 | $70.00 | $31.2K | 351 | 28 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Following our analysis of the options activities associated with Gilead Sciences, we pivot to a closer look at the company's own performance.
Gilead Sciences's Current Market Status
- Currently trading with a volume of 4,979,197, the GILD's price is up by 0.67%, now at $80.06.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 12 days.
Professional Analyst Ratings for Gilead Sciences
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $85.0.
- An analyst from Barclays has decided to maintain their Equal-Weight rating on Gilead Sciences, which currently sits at a price target of $85.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
